Objective To identify the incidence rate and incidence rate ratio (IRR) for COVID-19 breakthrough infection after SARS-CoV-2 vaccination among persons with or without immune dysfunction.ĭesign, Setting, and Participants This retrospective cohort study analyzed data from the National COVID Cohort Collaborative (N3C), a partnership that developed a secure, centralized electronic medical record–based repository of COVID-19 clinical data from academic medical centers across the US. However, these patients were largely excluded from SARS-CoV-2 vaccine clinical trials, creating a large evidence gap. Importance Persons with immune dysfunction have a higher risk for severe COVID-19 outcomes.
COVID TESTING CLEARVIEW WA FULL
We believe both full vaccination and COVID-19 natural immunity have independent roles in reducing breakthrough infection risk. On the other hand, in the model we presented in Table 3 and in a separate sensitivity analysis, we observed full vaccination also further reduced the risk of breakthrough infection among those individuals with a prior COVID-19 diagnosis. We interpret the current findings on prior infection to mean that a prior COVID-19 diagnosis can offer additional independent protection against COVID-19 and reduce the risk of breakthrough infection after partial or full vaccination. Therefore, all of them should have developed a certain degree of immune response due to vaccination.
acquired immunity against COVID-19 because all patients had received at least one dose of vaccine and the majority of them had completed all required doses of the vaccine. Our study was not designed to evaluate the effect of natural vs. A total of 141209 (21%) patients who had COVID-19 diagnoses prior to their vaccination in the study sample reported in Table 3. Thank you for your comment and interest in our research.įull vaccination was defined using the same definition for the entire study population, regardless of prior COVID diagnosis. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Additional Data Partners With Signed DTA and Pending Data Release Distribution of Patients Contributed by Each Institution Broken Down by A) Vaccination Status of at Least One Dose and B) COVID-19 DiagnosisĮAppendix.
Distribution of Patients Contributed by Each Submitting Institution for Each CohortĮMethods 5. List of 56 Data Partners Whose Data Is Available in the N3C EnclaveĮMethods 4. Example of How a Source Vocabulary Term Is Mapped to a OMOP Concept SetĮMethods 3. COVID-19 Disease Severity Comparing Cases Prior to Vaccination Versus Breakthrough Infection Cases Identified in N3C CohortĮMethods 2. Time to SARS-CoV-2 Post-Vaccine Breakthrough Infection Among Patients Completed All Required Dose of Vaccination by Immune Dysfunction Group in N3C Cohort, Decemto September 24, 2021ĮTable 4. Sensitivity Analyses for SARS-CoV-2 Infection After Vaccination Among N3C Cohort, Decemto September 24, 2021ĮTable 3. Key Variables and Concept DefinitionsĮTable 2. Geographic Region for Study Population in N3C, Decemto September 24, 2021ĮTable 1. Analytical Sample Selection Flow DiagramĮFigure 2.
0 kommentar(er)
